• April 29-30, 2016 Chicago, IL Registration Closed May 13-14, 2016 Los Angeles, CA Registration Closed October 21-22, 2016 New York, NY The Westin New York at
    Times Square
    November 4-5, 2016 Miami Beach, FL Fontainebleau
    Miami Beach

    Agenda At-a-Glance*

    * Please note the track order below does not reflect the individual agendas for each live course. Please see the live course locations tab for a detailed agenda.

    Breast Cancer Track

    Hereditary Breast and Ovarian Cancer Syndromes: Identification, Testing, and Management of High Risk Patients
    Judy E. Garber, MD, MPH

    HER2 Positive and Triple-Negative Breast Cancers: Current Evidence-Based Care and Recent Advances
    Eric P. Winer, MD

    ER Positive Breast Cancers: Incorporating New Therapies into Current Best Practices
    Harold J. Burstein, MD, PhD

    Supportive Care Track

    A Patient-Centered Approach to Palliative Care: Identifying Patient Needs and Managing Symptoms
    Janet L. Abrahm, MD

    Cancer Survivorship: Effective Strategies for Ongoing Care
    Ann H. Partridge, MD, MPH

    Genitourinary Cancers Track

    Advanced Prostate Cancer: Incorporating Recent Advances into Current Management Paradigms
    Robert Dreicer, MD

    Bladder and Renal Cancers: Best Practices for Treatment Selection and a Look Towards the Future
    Robert Dreicer, MD

    Head, Neck, and Lung Cancers Track

    Current Optimal Management Approaches for Head, Neck, and Thyroid Cancers
    Robert I. Haddad, MD

    Non-Small Cell and Small Cell Lung Cancer: Incorporating New Therapies into Personalized Treatment Regimens
    Bruce E. Johnson, MD

    Melanoma Cancer Track

    Making the Most of New Therapeutic Approaches to Malignant Melanoma
    F. Steven Hodi Jr., MD

    Gynecologic Cancer Track

    Gynecologic Cancers: Update on Recent Evidence-based Therapeutic Approaches and Emerging Systemic Therapies
    Ursula A. Matulonis, MD

    Gastrointestinal Cancer Track

    Systemic Treatments for Esophagogastric and Pancreas Cancers in Adjuvant and Metastatic Settings
    Peter C. Enzinger, MD

    Screening, Diagnosis, and Management Recommendations for Hereditary Gastrointestinal Cancers
    Sapna Syngal, MD, MPH

    Do Diet and Lifestyle Factors Influence Patients Survival? Emerging Data in GI Cancer Risk and Cancer Recurrence
    Charles S. Fuchs, MD, MPH

    Systemic Treatments for Colorectal Cancer in the Adjuvant and Metastatic Setting
    Robert J. Mayer, MD

    Hematologic Malignancies Track

    Non-Hodgkin and Hodgkin Lymphoma: Optimal Selection of Systemic Therapies
    Arnold S. Freedman, MD

    Myeloid Malignancies: Initial Treatment Selection and Ongoing Management Strategies
    Daniel J. DeAngelo, MD, PhD

    Managing Myeloproliferative Neoplasms: A Practical Approach
    Ayalew Tefferi, MD

    Current Evidence-Based Care and Emerging Therapies for Multiple Myeloma
    Kenneth C. Anderson, MD

    Chronic Lymphocytic Leukemia: Incorporating Targeted Therapies into Optimal Management
    John C. Byrd, MD

    Course Goal and Overview

    The goal of this course is to assist oncologists with assessing and improving their skills in the diagnosis, treatment, and overall management of a wide range of common cancers.

    This innovative, live two-day curriculum provides a comprehensive update of oncologic practice, including current best practices and updated guidelines, emerging clinical evidence, and recent expert opinion in nearly all major areas of practice. Highly interactive presentations are followed by lively discussion sessions, including both Q&A and panel discussion formats. Learners are encouraged to bring their most difficult cases and clinical questions, building clinical skills through exposure to practice and patient care standards set by the acknowledged master clinicians of DFCI.

    Target Audience

    This course is intended for Medical Oncologists seeking an in depth review of the latest treatment advances in oncology.

    Maintenance of Certification (MOC) Session***

    *** Please sign up when registering for the course to participate in our optional MOC session.

    Optional Maintenance of Certification (MOC Part II ) Session 2016 Updates in Oncology

    Harold J. Burstein, MD, PhD
    Daniel J. DeAngelo, MD, PhD
    Robert J. Mayer, MD

  • Acknowledgments

    Dana-Farber Cancer Institute gratefully acknowledges the following organizations for providing educational grants or financial support at the time of print for this activity.

    Amgen Boehringer Ingelheim Bristol-Myers Squibb
    Celegene Eli Lilly Genomic Health
    Merck Millennium Novartis
    Otsuka Pharmacyclics Taiho Oncology